Venture capital firm Dimension Capital has successfully closed its third fund, securing $800 million. This significant capital raise underscores the growing investor confidence in companies operating at the nexus of scientific innovation and advanced computing. The new fund represents a substantial increase, marking a 60% growth from its previous $500 million vehicle raised just 18 months prior.

Founded in late 2022 by former Lux Capital partners Zavian Dar and Adam Goulburn, alongside Nan Li from Obvious Ventures, Dimension Capital was built on the conviction that founders would increasingly establish deep-tech enterprises bridging the fields of biotechnology and software. The firm’s partners have expressed their satisfaction with the rapid validation of this investment thesis, observing a swift acceleration in the development of such groundbreaking companies.

Dimension Capital’s recent investment activities highlight its strategic focus. In 2024, the firm co-led a $30 million seed round for Chai Discovery, a startup developing open-source AI foundation models specifically for drug development. This investment preceded Chai Discovery’s recent announcement of a $400 million funding round at a $3.8 billion valuation. Additionally, Dimension Capital supported the anti-aging startup New Limit during its Series A funding in early 2025. New Limit, co-founded by Coinbase CEO Brian Armstrong, has since achieved a $3.1 billion valuation following its Series C round.

Further demonstrating its successful track record, Dimension Capital has backed other notable ventures, including inference company Modal Labs. The firm also holds shares in AI giant Anthropic, a stake acquired after Anthropic’s purchase of Dimension’s portfolio company, Coefficient Bio, a drug discovery platform, for an estimated $400 million this past spring.

Key Takeaways

• Dimension Capital has closed an $800 million fund, indicating strong investor interest in the science and compute intersection.
• The firm's investment strategy focuses on deep-tech companies blending biotech and software, with successful backing of startups like Chai Discovery and New Limit.
• Dimension Capital's portfolio includes AI companies and drug discovery platforms, reflecting a trend towards AI-driven scientific advancement.

Editor’s Analysis & Impact

The substantial growth of Dimension Capital’s fund size signals a robust and expanding market for deep-tech ventures that integrate biological sciences with cutting-edge computational power. This trend is particularly evident in areas like AI-driven drug discovery and advanced biotech solutions. Investors are increasingly recognizing the potential for significant returns as these fields mature and demonstrate tangible progress. The success of Dimension Capital’s strategy suggests a broader industry shift, where traditional scientific research is being augmented and accelerated by technological innovation, creating fertile ground for new breakthroughs and market leaders.

Frequently Asked Questions

Q: What is Dimension Capital's investment focus?
A: Dimension Capital focuses on investing in deep-tech companies that operate at the intersection of science and compute, particularly those bridging biotechnology and software.

Q: What are some notable companies Dimension Capital has invested in?
A: Notable investments include Chai Discovery, New Limit, Modal Labs, and Anthropic. They also had a stake in Coefficient Bio, which was acquired by Anthropic.

Q: Why is the intersection of science and compute a growing area for investment?
A: Advancements in computing power, particularly AI and machine learning, are enabling faster and more sophisticated research and development in scientific fields like biotechnology, leading to potential breakthroughs and significant market opportunities.